 | • レポートコード：MRC2304E087 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に249.38百万ドルであった世界のアセタゾラミド市場規模が、2022年に264.82百万ドルに達し、2027年には361.18百万ドルまで年平均6.36%で成長すると予測しています。当レポートは、アセタゾラミドの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、剤形別（カプセル剤、注射剤、錠剤）分析、疾患別（高山病、てんかん、緑内障、心不全、その他）分析、流通チャネル別（病院、通販サイト、ドラッグストア）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめています。なお、当書には、Aquatic Group、Avanscure Lifesciences Pvt Ltd.、CTX Lifesciences Pvt Ltd、Emcure Pharmaceuticals Limited、Heritage Pharmaceuticals Inc、Lannett Co Inc、Lannett Company, Inc、LGM Pharma、Manus Aktteva Biopharma LLP、Mylan N.V.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のアセタゾラミド市場規模：剤形別 - カプセル剤の市場規模 - 注射剤の市場規模 - 錠剤の市場規模 ・世界のアセタゾラミド市場規模：疾患別 - 高山病の市場規模 - てんかんの市場規模 - 緑内障の市場規模 - 心不全の市場規模 - その他疾患の市場規模 ・世界のアセタゾラミド市場規模：流通チャネル別 - 病院チャネルにおける市場規模 - 通販サイトチャネルにおける市場規模 - ドラッグストアチャネルにおける市場規模 ・世界のアセタゾラミド市場規模：地域別 - 南北アメリカのアセタゾラミド市場規模 アメリカのアセタゾラミド市場規模 カナダのアセタゾラミド市場規模 ブラジルのアセタゾラミド市場規模 … - アジア太平洋のアセタゾラミド市場規模 日本のアセタゾラミド市場規模 中国のアセタゾラミド市場規模 インドのアセタゾラミド市場規模 韓国のアセタゾラミド市場規模 台湾のアセタゾラミド市場規模 … - ヨーロッパ/中東/アフリカのアセタゾラミド市場規模 イギリスのアセタゾラミド市場規模 ドイツのアセタゾラミド市場規模 フランスのアセタゾラミド市場規模 ロシアのアセタゾラミド市場規模 … - その他地域のアセタゾラミド市場規模 ・競争状況 ・企業情報 |
The Global Acetazolamide Market size was estimated at USD 249.38 million in 2021 and expected to reach USD 264.82 million in 2022, and is projected to grow at a CAGR 6.36% to reach USD 361.18 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Acetazolamide to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Dosage Form, the market was studied across Capsules, Injection, and Tablets.
Based on Disease, the market was studied across Altitude Sickness, Epilepsy, Glaucoma, Heart Failure, Idiopathic Intracranial Hypertension, and Periodic Paralysis.
Based on Distribution Channel, the market was studied across Hospital, Online Drug Store, and Retail Drug Store.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Acetazolamide market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Acetazolamide Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Acetazolamide Market, including Aquatic Group, Avanscure Lifesciences Pvt Ltd., CTX Lifesciences Pvt Ltd, Emcure Pharmaceuticals Limited, Heritage Pharmaceuticals Inc, Lannett Co Inc, Lannett Company, Inc, LGM Pharma, Manus Aktteva Biopharma LLP, Mylan N.V., Nakoda Chemicals Ltd., Ningbo Hi-tech Biochemicals Co Ltd, Nostrum Laboratories Inc, Novast Laboratories Ltd., Polpharma SA, Shandong Octagon Chemicals Limited, Strides Pharma Science Limited, Strides Shasun Limited, Sun Pharmaceutical Industries, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, West-Ward Pharmaceutical Corp., X-Gen Pharmaceuticals, Inc., and Zydus Pharmaceuticals (USA) Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Acetazolamide Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Acetazolamide Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acetazolamide Market?
4. What is the competitive strategic window for opportunities in the Global Acetazolamide Market?
5. What are the technology trends and regulatory frameworks in the Global Acetazolamide Market?
6. What is the market share of the leading vendors in the Global Acetazolamide Market?
7. What modes and strategic moves are considered suitable for entering the Global Acetazolamide Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of glaucoma and pertinent risk factors such as high blood pressure among the population
5.1.1.2. Increasing healthcare infrastructure
5.1.1.3. Application of acetazolamide in several treatment modalities
5.1.2. Restraints
5.1.2.1. Concerns related to certain glitches during production process
5.1.2.2. Augmenting availability of acetazolamide as generic medicine
5.1.3. Opportunities
5.1.3.1. Rising innovation in the production of varied types of acetazolamide
5.1.3.2. Augmenting availability of acetazolamide as generic medicine
5.1.4. Challenges
5.1.4.1. Availability of considerable alternatives to acetazolamide in the market
5.2. Cumulative Impact of COVID-19
6. Acetazolamide Market, by Dosage Form
6.1. Introduction
6.2. Capsules
6.3. Injection
6.4. Tablets
7. Acetazolamide Market, by Disease
7.1. Introduction
7.2. Altitude Sickness
7.3. Epilepsy
7.4. Glaucoma
7.5. Heart Failure
7.6. Idiopathic Intracranial Hypertension
7.7. Periodic Paralysis
8. Acetazolamide Market, by Distribution Channel
8.1. Introduction
8.2. Hospital
8.3. Online Drug Store
8.4. Retail Drug Store
9. Americas Acetazolamide Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Acetazolamide Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Acetazolamide Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Aquatic Group
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Avanscure Lifesciences Pvt Ltd.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. CTX Lifesciences Pvt Ltd
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Emcure Pharmaceuticals Limited
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Heritage Pharmaceuticals Inc
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Lannett Co Inc
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Lannett Company, Inc
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. LGM Pharma
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Manus Aktteva Biopharma LLP
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Mylan N.V.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Nakoda Chemicals Ltd.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Ningbo Hi-tech Biochemicals Co Ltd
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Nostrum Laboratories Inc
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Novast Laboratories Ltd.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Polpharma SA
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Shandong Octagon Chemicals Limited
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Strides Pharma Science Limited
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Strides Shasun Limited
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sun Pharmaceutical Industries
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Taro Pharmaceutical Industries Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Teva Pharmaceutical Industries Ltd
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. West-Ward Pharmaceutical Corp.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. X-Gen Pharmaceuticals, Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Zydus Pharmaceuticals (USA) Inc.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing